Granules India’s stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company’s product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.
RR Kabel shares jump 10% as Q1 PAT surges 129% YoY, Ebitda doubles
RR Kabel reported a strong June-quarter performance, with profit after tax surging 129% year-on-year and Ebitda nearly doubling, driven by robust growth in its Wires